Page 212 - The Vasculitides Volumes 2

188 Kelly G. Gwathmey, Jennifer A. Tracy and P. James B. Dyck

[32] Ntatsaki, E., Watts, R. A., Scott, D. G. I. Epidemiology of ANCA-associated vasculitis.
Rheum. Dis. Clin. North Am. 2010; 36:447-461.

[33] Mahr, A. D. Epidemiological features of Wegener?s granulomatosis and microscopic
polyangiitis: two diseases or one “anti-neutrophil cytoplasm antibodies-associated
vasculitis” entity? APMIS Suppl. 2009; 127:41-47.

[34] Mohammad, A. J., Jacobsson, L. T. H., Westman, K. W. A., et al. Incidence and
survival rates in Wegener?s granulomatosis, microscopic polyangiitis, Churg-Strauss
syndrome and polyarteritis nodosa. Rheumatology 2009; 48:1560-1565.

[35] Collins, M. P., Arnold, W. D., Kissel, J. T. The neuropathies of vasculitis. Neurol. Clin.
2013; 31:557-595.

[36] Guillevin, L., Durand-Gasselin, B., Cevallos, R., et al. Microscopic polyangiitis:
clinical and laboratory findings in eighty-five patients. Arthritis Rheum. 1999; 42:421-
430.

[37] Cattaneo, L., Chierici, E., Pavone, L., et al. Peripheral neuropathy in Wegener?s
granulomatosis, Churg-Strauss syndrome and microscopic polyangiitis. J. Neurol.
Neurosurg. Psychiatry 2007; 78:1119-1123.

[38] Cisternas, M., Soto, L., Jacobelli, S., et al. [Clinical features of Wegener
granulomatosis and microscopic polyangiitis in Chilean patients]. Rev. Med. Chil. 2005;
133:273-278.

[39] Ahn, J. K., Hwang, J.-W., Lee, J., Jeon et al. Clinical features and outcome of
microscopic polyangiitis under a new consensus algorithm of ANCA-associated
vasculitides in Korea. Rheumatol. Int. 2012; 32:2979-2986.

[40] Zhang, W., Zhou, G., Shi, Q., et al. Clinical analysis of nervous system involvement in
ANCA-associated systemic vasculitides. Clin. Exp. Rheumatol. 2009; 27:S65-69.

[41] Oh, J. S., Lee, C.-K., Kim, Y. G., et al. Clinical features and outcomes of microscopic
polyangiitis in Korea. J. Korean Med. Sci. 2009; 24:269-274.

[42] Lanham, J. G., Elkon, K. B., Pusey, C. D., et al. Systemic vasculitis with asthma and
eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine 1984; 63:
65-81.

[43] Keogh, K. A., Specks, U. Churg-Strauss syndrome: clinical presentation, antineutrophil
cytoplasmic antibodies, and leukotriene receptor antagonists. Am. J. Med. 2003; 115:
284-290.

[44] Sinico, R. A., Di Toma, L., Maggiore, U., et al. Prevalence and clinical significance of
antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum.
2005; 52:2926-2935.

[45] Comarmond, C., Pagnoux, C., Khellaf, M., et al. Eosinophilic granulomatosis with
polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383
patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum. 2013;
65:270-281.

[46] Moosig, F., Bremer, J. P., Hellmich, B., et al. A vasculitis centre based management
strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis
(Churg-Strauss, EGPA): monocentric experiences in 150 patients. Ann. Rheum. Dis.
2013; 72:1011-1017.

[47] Vinit, J., Muller, G., Bielefeld, P., et al. Churg-Strauss syndrome: retrospective study in
Burgundian population in France in past 10 years. Rheumatol. Int. 2011; 31:587-593.

Complimentary Contributor Copy